近日，国家药品监督管理局发布新规，要求中成药说明书必须明确标注不良反应、禁忌及注意事项等内容，标志着中成药正式告别“尚不明确”时代。这一政策旨在提升药品信息透明度，保障患者用药安全，推动中医药规范化、科学化发展。长期以来，部分中成药说明书存在关键信息缺失问题，导致医生和患者难以全面评估用药风险。新规实施后，生产企业需依据临床数据和科学证据完善说明书，强化责任意识。此举不仅增强公众对中成药的信任，也促进中医药与国际标准接轨，为传统医药现代化注入新动力。
Recently, the National Medical Products Administration issued new regulations requiring traditional Chinese patent medicine (TCPM) instructions to clearly label adverse reactions, contraindications, and precautions, marking the end of the era of “not yet clear” information. This policy aims to enhance drug information transparency, ensure medication safety, and promote the standardized and scientific development of traditional Chinese medicine. For a long time, some TCPM instructions lacked critical information, making it difficult for doctors and patients to fully assess medication risks. Under the new rules, manufacturers must improve instructions based on clinical data and scientific evidence, strengthening accountability. This move not only boosts public trust in TCPM but also facilitates alignment with international standards, injecting new momentum into the modernization of traditional medicine.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/23462.html